Chengdu Easton Biopharmaceuticals Past Earnings Performance
Past criteria checks 1/6
Chengdu Easton Biopharmaceuticals has been growing earnings at an average annual rate of 16.6%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 5.7% per year. Chengdu Easton Biopharmaceuticals's return on equity is 9.2%, and it has net margins of 20.8%.
Key information
16.6%
Earnings growth rate
10.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 5.7% |
| Return on equity | 9.2% |
| Net Margin | 20.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Chengdu Easton Biopharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,154 | 241 | 496 | 242 |
| 31 Dec 23 | 1,117 | 227 | 483 | 237 |
| 30 Sep 23 | 1,123 | 245 | 494 | 234 |
| 30 Jun 23 | 1,150 | 243 | 534 | 237 |
| 31 Mar 23 | 1,179 | 254 | 559 | 235 |
| 31 Dec 22 | 1,171 | 247 | 566 | 230 |
| 30 Sep 22 | 1,147 | 242 | 561 | 217 |
| 30 Jun 22 | 1,100 | 250 | 544 | 205 |
| 31 Mar 22 | 1,071 | 243 | 542 | 203 |
| 31 Dec 21 | 1,023 | 232 | 526 | 200 |
| 30 Sep 21 | 1,023 | 239 | 552 | 191 |
| 30 Jun 21 | 986 | 209 | 539 | 181 |
| 31 Mar 21 | 967 | 191 | 546 | 169 |
| 31 Dec 20 | 922 | 178 | 528 | 153 |
| 30 Sep 20 | 942 | 139 | 573 | 148 |
| 30 Jun 20 | 907 | 115 | 576 | 146 |
| 31 Mar 20 | 886 | 100 | 579 | 144 |
| 31 Dec 19 | 947 | 109 | 624 | 156 |
| 31 Dec 18 | 769 | 135 | 458 | 124 |
| 31 Dec 17 | 476 | 64 | 276 | 77 |
| 30 Jun 16 | 250 | 44 | 110 | 0 |
| 31 Mar 16 | 245 | 41 | 99 | 0 |
| 31 Dec 15 | 241 | 38 | 87 | 0 |
| 01 Jan 15 | 209 | 29 | 70 | 0 |
| 31 Dec 13 | 162 | 15 | 54 | 0 |
Quality Earnings: 688513 has a large one-off gain of CN¥64.6M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 688513's current net profit margins (20.8%) are lower than last year (21.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688513's earnings have grown by 16.6% per year over the past 5 years.
Accelerating Growth: 688513's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 688513 had negative earnings growth (-5.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.5%).
Return on Equity
High ROE: 688513's Return on Equity (9.2%) is considered low.